Historic CRISPR drug approval heralds new era in Cas9 IP wars
Green light for first ever Cas9 therapy ushers in next phase of licensing and litigation efforts.
Green light for first ever Cas9 therapy ushers in next phase of licensing and litigation efforts.
Chief Legal Officer Yoori Kim argues that current patent uncertainty should fuel rather than thwart licensing deals
The surge is due to 9,702 US patent assets involved in the BlackBerry sale to Key Patent Innovations, which runs Malikie Innovations, according to the AST Patent Deals Report for Q2 2023
Terran Biosciences has emerged from obscurity to snap up slew of IP rights in the past two months
04 May 2022
NortonLifeLock has pledged to appeal the jury verdict, which could balloon to $550 million with enhanced damages for wilful infringement
03 May 2022
Following major US CRISPR decision, Michael Arciero, VP of IP at ERS Genomics, tells IAM that tricky patent landscapes are the new normal in biotech
04 April 2022
Returning from two action-packed days in London, IAM Deputy Editor Adam Houldsworth reflects on the surprising state of corporate UPC strategies, the rise of AI, FRAND fireworks and more
02 April 2022
Larry Horn speaks exclusively to IAM about the future of biotech joint licensing programmes
25 March 2022
The grace period gap between major jurisdictions has recently been thrust into the spotlight. The JPO is one stakeholder pushing for major players to seize momentum and work towards harmonisation
23 March 2022
Deal announced by French pharma giant this week is highly distinctive, but also reflects several recent trends in the booming drug revenue market
17 March 2022
There are reports of a compromise deal agreeed by the US, EU, India and South Africa, but no official confirmation
16 March 2022
Petro Terblanche speaks to IAM about the mRNA innovator’s expanded IP commitment
14 March 2022
A recent deal shows that a wider selection of corporates are exploring acquisition opportunities and working with custom R&D labs
08 March 2022
Unlock unlimited access to all IAM content